New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation.
about
Protein Ser/Thr phosphatases--the ugly ducklings of cell signalling.Influence of MRP2 on MPA pharmacokinetics in renal transplant recipients-results of the Pharmacogenomic Substudy within the Symphony Study.Expression of IMPDH mRNA after mycophenolate administration in male volunteers.Serologic vaccination response after solid organ transplantation: a systematic review.The Calcineurin Inhibitor-Sparing (CIS) Trial - individualised calcineurin-inhibitor treatment by immunomonitoring in renal allograft recipients: protocol for a randomised controlled trial.Calcineurin inhibitors differentially alter the circadian rhythm of T-cell functionality in transplant recipientsThe use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients.Influence of sex and race on mycophenolic acid pharmacokinetics in stable African American and Caucasian renal transplant recipients.Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocritPopulation pharmacokinetic analysis of tacrolimus in Mexican paediatric renal transplant patients: role of CYP3A5 genotype and formulation.Association of Extrarenal Adverse Effects of Posttransplant Immunosuppression With Sex and ABCB1 Haplotypes.Pharmacokinetics, Pharmacodynamics and Pharmacogenomics of Immunosuppressants in Allogeneic Haematopoietic Cell Transplantation: Part IGenotype-guided tacrolimus dosing in African-American kidney transplant recipients.Matched-pair analysis: identification of factors with independent influence on the development of PTLD after kidney or liver transplantation.Application of Machine-Learning Models to Predict Tacrolimus Stable Dose in Renal Transplant Recipients.Pharmacokinetic Assessment of Drug-Drug Interactions of Isavuconazole With the Immunosuppressants Cyclosporine, Mycophenolic Acid, Prednisolone, Sirolimus, and Tacrolimus in Healthy Adults.Impact of Mycophenolate Mofetil Dose Reduction on Allograft Outcomes in Kidney Transplant Recipients on Tacrolimus-Based Regimens: A Systematic Review.Belatacept: a novel biologic for maintenance immunosuppression after renal transplantation.Generic maintenance immunosuppression in solid organ transplant recipients.Advances in the current treatment of autoimmune hepatitis.Drug choices in autoimmune hepatitis: part B--Nonsteroids.Genes and beans: pharmacogenomics of renal transplant.Do Asian renal transplant patients need another mycophenolate mofetil dose compared with Caucasian or African American patients?Tacrolimus prolonged release (Envarsus®): a review of its use in kidney and liver transplant recipients.Generic immunosuppression in transplantation: current evidence and controversial issues.Dosing algorithms for initiation of immunosuppressive drugs in solid organ transplant recipients.Advances in pharmacotherapy to treat kidney transplant rejection.Impact of intrapatient variability (IPV) in tacrolimus trough levels on long-term renal transplant function: multicentre collaborative retrospective cohort study protocol.Correlation between pharmacokinetics and pharmacodynamics of mycophenolic acid in liver transplant patients.Update on the clinical pharmacogenomics of organ transplantation.Safety and efficacy of the switch to generic mycophenolate mofetil and tacrolimus in heart transplant patients.Using genetic and clinical factors to predict tacrolimus dose in renal transplant recipients.Enteric-coated mycophenolate sodium.Race and drug formulation influence on mycophenolic acid pharmacokinetics in stable renal transplant recipients.Immune function assay (ImmuKnow) as a predictor of allograft rejection and infection in kidney transplantation.In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients.The CYP3A4*22 C>T single nucleotide polymorphism is associated with reduced midazolam and tacrolimus clearance in stable renal allograft recipients.Sex differences in cyclosporine pharmacokinetics and ABCB1 gene expression in mononuclear blood cells in African American and Caucasian renal transplant recipients.In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients.Tacrolimus concentration to dose ratio in solid organ transplant patients treated with fecal microbiota transplantation for recurrent Clostridium difficile infection.
P2860
Q30455386-5AB5BB30-5D0F-4E78-ABA8-D7B7DB34412CQ33852812-494DE36E-5B81-4C4A-8DFB-95BB380D04B9Q33912025-406BE2CC-8E37-425A-BE24-E5C35B91030EQ34602836-4882D116-9A90-43E0-9398-135566F981CCQ34995106-2293D955-437C-473D-826C-A5FF9DC162FAQ35085619-6C260FD8-2FE5-43C5-BF55-52D64CC8BB84Q35612903-2B5618B4-B71B-48EE-96EF-982A9522027AQ35619332-9045B849-8AF0-4731-BDB4-1858B49E3B80Q36072508-CBA6F519-BA8D-4639-ABC5-D53152471BE7Q36125433-D52FEF46-BE3A-44A7-8AD6-B09FCF94B2E7Q36256056-93D91775-07EE-4AAB-83A0-450E0C834D8CQ36777599-C0BD1049-F121-462A-98C2-C195536F2BE7Q37009025-E2A43732-4300-4610-BEC3-D78B29C0829BQ37145738-8E48B0D4-83B8-474C-A84B-4466998B50D7Q37630718-59CC6608-38AC-4445-AF9E-6E228C867B1BQ37631892-98A7E1B2-7BA5-4ED6-AD36-0AEF22CBB03FQ37838123-F6F239F6-AF0A-45F1-A37F-CBCDB54B80A4Q37859368-29E81FBD-4A4A-4232-9F93-EAE13C6D4B60Q37949392-060383CD-6E1C-48E4-BBF0-627C8E98D4E8Q38000056-8E9C2558-AC75-4937-8D87-9A0C1530CB66Q38051706-847D6405-C56C-434E-9D8F-D58F0F0346F8Q38104742-D60B7A65-26CC-49FD-97CC-5AE36069242CQ38223136-29017F29-1631-48F8-B0A7-F66A7D3C8F5EQ38329297-F56D0964-DCDA-4D15-B03C-B693AEA956E3Q38393905-3D215F78-3E7F-4DDA-95F1-84478990F4BDQ38417581-FB60FE84-FBD0-4624-B34C-963CDD4842EEQ38544529-FE91FB27-E7B3-45B5-A902-1596D2A0EF94Q38653411-0B2DE161-ACC7-46CC-8CA6-E4D7C49A7110Q39729251-227C38CF-CBF6-4D06-813F-2013EDFC7914Q39903042-1FD60D75-09B2-4D21-B809-8483E4237682Q41733509-BC697D8D-3958-41B4-BC6B-6ED4A8FD5F5DQ42837771-2A2D8B5E-D8AB-4452-9772-3C108E79EAECQ42925114-773B34AE-B1DA-457D-B300-58A4FD75998FQ44447188-D5B3CB67-AD45-4302-994D-CC8C28DFE40CQ45369105-58D420B9-969A-4442-8C86-0A4CB068EF4CQ47292609-6B1A85FA-D9CE-4BBC-9C89-02E20F91E93AQ47803890-01D4FDCE-ECAF-4541-983E-3B9DA93D0913Q47877438-306BA73B-67F5-4254-A3B1-364FD4146552Q48247827-B1056558-A280-4286-B8CA-0BB67073B962Q49984624-04E28966-B970-45C2-97FE-311A29DE1387
P2860
New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
New insights into the pharmaco ...... n solid organ transplantation.
@en
New insights into the pharmaco ...... n solid organ transplantation.
@nl
type
label
New insights into the pharmaco ...... n solid organ transplantation.
@en
New insights into the pharmaco ...... n solid organ transplantation.
@nl
prefLabel
New insights into the pharmaco ...... n solid organ transplantation.
@en
New insights into the pharmaco ...... n solid organ transplantation.
@nl
P2093
P1476
New insights into the pharmaco ...... n solid organ transplantation.
@en
P2093
Dirk R J Kuypers
Hylke de Jonge
Maarten Naesens
P304
P356
10.1097/FTD.0B013E3181AA36CD
P577
2009-08-01T00:00:00Z